Structural basis of HIV inhibition by translocationdefective RT inhibitor 4′-ethynyl-2-fluoro-2′- deoxyadenosine (EFdA)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 33, 2016, Pages 9274-9279

  Salie, Zhe Li ^a   Kirby, Karen A ^a   Michailidis, Eleftherios ^a   Marchand, Bruno ^a   Singh, Kamalendra ^a   Rohan, Lisa C ^b,c   Kodama, Eiichi N ^d   Mitsuya, Hiroaki ^e,f,g   Parniak, Michael A ^h   Sarafianos, Stefan G ^a  

^a University of Missouri   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d TOHOKU UNIVERSITY   (Japan)

^e NATIONAL CANCER INSTITUTE   (United States)

^f KUMAMOTO UNIVERSITY   (Japan)

^g NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

EFdA; HIV 1 reverse transcriptase; Inhibitors; Nrtis; X ray crystallography

Indexed keywords

4' ETHYNYL 2 FLUORO 2' DEOXYADENOSINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYADENOSINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA; 4'-ETHYNYL-2-FLUORO-2'-DEOXYADENOSINE; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA BINDING; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STABILITY; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; CHEMISTRY; X RAY CRYSTALLOGRAPHY;

ANTI-HIV AGENTS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DEOXYADENOSINES; ENZYME STABILITY; HIV REVERSE TRANSCRIPTASE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 85047289150     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1605223113     Document Type: Article

References (26)

1. Woo G, et al. (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian meta- Analyses. Gastroenterology 139(4):1218-1229.
2. Michailidis E, et al. (2012) Antiviral therapies: Focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol 44(7):1060-1071.
3. Lawitz E, et al. (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368(20):1878-1887.
4. Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G (2013) A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 20(30):3733-3742.
5. Takamatsu Y, et al. (2015) 4′-Modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus. Hepatology 62(4):1024-1036.
6. Kawamoto A, et al. (2008) 2′-Deoxy-4′-C-ethynyl-2-halo- Adenosines active against drugresistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol 40(11): 2410-2420.
7. Michailidis E, et al. (2009) Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem 284(51):35681-35691.
8. Ohrui H (2006) 2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Rec 6(3):133-143.
9. Grobler J, et al. (2016) Long- Acting oral and parenteral dosing of MK-8591 for HIV treatment or prophylaxis. In Special Issue: Abstracts from the 2016 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med 24(e-1):391.
10. Kageyama M, Nagasawa T, Yoshida M, Ohrui H, Kuwahara S (2011) Enantioselective total synthesis of the potent anti-HIV nucleoside EFdA. Org Lett 13(19):5264-5266.
11. Kirby KA, et al. (2013) Effects of substitutions at the 4′ and 2 positions on the bioactivity of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob Agents Chemother 57(12):6254-6264.
12. Stoddart CA, et al. (2015) Oral administration of the nucleoside EFdA (4′-ethynyl-2- fluoro-2′-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. Antimicrob Agents Chemother 59(7):4190-4198.
13. Hachiya A, et al. (2013) Evaluation of combinations of 4′-ethynyl-2-fluoro-2′-deoxyadenosine with clinically used antiretroviral drugs. Antimicrob Agents Chemother 57(9):4554-4558.
14. Murphey-Corb M, et al. (2012) Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo. Antimicrob Agents Chemother 56(9):4707-4712.
15. Michailidis E, et al. (2014) 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem 289(35):24533-24548.
16. Singh K, Marchand B, Kirby KA, Michailidis E, Sarafianos SG (2010) Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruses 2(2):606-638.
17. Sarafianos SG, et al. (2002) Structures of HIV-1 reverse transcriptase with pre- And post- Translocation AZTMP- Terminated DNA. EMBO J 21(23):6614-6624.
18. Nakata H, et al. (2007) Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro- 2′-deoxyadenosine. Antimicrob Agents Chemother 51(8):2701-2708.
19. Huang H, Chopra R, Verdine GL, Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 282(5394):1669-1675.
20. Sarafianos SG, et al. (2003) Trapping HIV-1 reverse transcriptase before and after translocation on DNA. J Biol Chem 278(18):16280-16288.
21. Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66(Pt 2):125-132.
22. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(Pt 4):658-674.
23. Winn MD, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67(Pt 4):235-242.
24. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
25. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58(Pt 11):1948-1954.
26. Moriarty NW, Grosse-Kunstleve RW, Adams PD (2009) Electronic ligand builder and optimization workbench (eLBOW): A tool for ligand coordinate and restraint generation. Acta Crystallogr D Biol Crystallogr 65(Pt 10):1074-1080.